Caribou Biosciences (CRBU) Stock Statistics & Valuation Metrics

Caribou Biosciences has a market cap or net worth of $180.71M. The enterprise value is $199.00M.

Caribou Biosciences has 96,637,200 shares outstanding. The number of shares has decreased by -2.65% in one year.

Caribou Biosciences’s return on equity (ROE) is -1.21 and return on invested capital (ROIC) is -89.77%.

The current PE Ratio of Caribou Biosciences is ―. Caribou Biosciences’s PEG ratio is 0.28.

In the last 12 months, Caribou Biosciences had revenue of 11.16M and earned -148.13M in profits. Earnings per share was -1.59.

In the last 12 months, operating cash flow was -110.99M and capital expenditures -1.36M, giving a free cash flow of -112.35M billion.

Caribou Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Caribou Biosciences upcoming earnings date is May 12, 2026, After Close (Confirmed).

Caribou Biosciences as a current ratio of 5.71, with Debt / Equity ratio of 22.29%

In the past 12 months, Caribou Biosciences has paid -550.00K in taxes.

Caribou Biosciences EV to EBITDA ratio is -1.23, with an EV/FCF ratio of -1.45.

Caribou Biosciences has $139.34M in cash and marketable securities with $27.23M in debt, giving a net cash position of $112.11M billion.

Gross margin is 88.23%, with operating margin of -1220.49%, and net profit margin of -1327.40%.

The average price target for Caribou Biosciences is $8.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy